{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:43:23Z","timestamp":1767890603987,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["B19249AT"],"award-info":[{"award-number":["B19249AT"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31870809"],"award-info":[{"award-number":["31870809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703598"],"award-info":[{"award-number":["81703598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801335"],"award-info":[{"award-number":["81801335"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Rapid Comm Mass Spectrometry"],"published-print":{"date-parts":[[2022,11,15]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Anlotinib is a multi\u2010target tyrosine kinase inhibitor, approved in China for treating several cancer types. Dose individualization based on therapeutic drug monitoring (TDM) is a useful tool to reduce toxicity. However, it is not convenient for patients to go to hospital for routine TDM via venous blood sampling at a certain time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An ultra\u2010performance liquid chromatography tandem mass spectrometry (UPLC\u2013MS\/MS) method was developed and validated for determination of anlotinib in human plasma and dried blood spot (DBS), characterized by simple sample preparation, high sensitivity, and short analysis time. The assay was validated in the concentration range of 0.2\u2013200\u2009ng\/mL in plasma and 5\u20131000\u2009ng\/mL in DBS. This method was applied to monitor anlotinib exposure levels in patients with advanced biliary tract cancer (BTC) and non\u2010small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The trough plasma concentration (C\n                      <jats:sub>trough<\/jats:sub>\n                      ) of anlotinib was highly variable among BTC patients with coefficients of variation (CV) of 47.5%. DBS and venous blood samples were also collected from NSCLC patients to determine whether DBS sampling is a viable alternative sampling approach. Pearson correlation coefficient (R) between DBS and plasma concentration was 0.985. Bland\u2013Altman plot demonstrated that the difference between estimated and measured plasma concentration was \u22122.9%. And 87% of sample pairs had a maximal deviation of \u00b120%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anlotinib exhibits a high inter\u2010individual variability in plasma exposure, and DBS sampling could be a promising tool for TDM of anlotinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/rcm.9372","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T22:29:01Z","timestamp":1659479341000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A rapid and sensitive ultra\u2010performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-3145","authenticated-orcid":false,"given":"Ji","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikai","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biological Sample Bank The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou University  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100939\u2010x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010018\u20100664\u20107"},{"key":"e_1_2_7_4_1","unstructured":"Chia Tai Tianqing Pharmaceutical.Anlotinib hydrochloride capsules.2018.https:\/\/www.cttq.com. Accessed May 29 2018."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11685"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201017\u20103766"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3771"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018\u20100839"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072\u2010021\u201010171\u20100"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9110668"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.09.007"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010014\u20100137\u20102"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(13)70579\u20105"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010016\u20100332\u20108"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e17071"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.199"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080112"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094\u2010016\u20101509\u2010x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122752"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1039\/c9an00861f"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.21109"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113597"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010021\u201003036\u20106"},{"key":"e_1_2_7_25_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration.Guidance for Industry Bioanalytical Method Validation 2018.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalyticalmethod-validation-guidance-industry"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000643"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.8b02046"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13124"},{"key":"e_1_2_7_29_1","unstructured":"European Medicines Agency.Guideline on Bioanalytical Method Validation (2011).https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guidelinebioanalytical-method-validation_en.pdf"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.07.011"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114418"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114623"}],"container-title":["Rapid Communications in Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.9372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rcm.9372","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rcm.9372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:34:14Z","timestamp":1761492854000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/rcm.9372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":31,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11,15]]}},"alternative-id":["10.1002\/rcm.9372"],"URL":"https:\/\/doi.org\/10.1002\/rcm.9372","archive":["Portico"],"relation":{},"ISSN":["0951-4198","1097-0231"],"issn-type":[{"value":"0951-4198","type":"print"},{"value":"1097-0231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"2022-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e9372"}}